Diabetes increases Gastric Cancer risk after treatment for H. Pylori infection, finds study
Type 2 diabetes mellitus is associated with gastric cancer after H. Pylori infection treatment, revealed a study published in the Journal of Diabetes Care.
Gastric cancer (GC) is one of the major death-causing cancers worldwide. A number of prior studies have shown an association between Helicobacter Pylori infection and gastric cancer. Diabetes mellitus (DM) is a common and major disease worldwide. Increasing evidence indicates that patients with DM have a higher risk of not only cardiovascular disease but also cancer in various organs. Recently, several investigators have found a possible association between DM and liver, uterus, colon gastric cancers.
The present study was conducted to investigate whether type 2 DM increased risk of Gastric cancer(GC) in patients after they received treatment for H. Pylori infection. In order to achieve this, a team of researchers from the University of Hong Kong and University College London conducted territory-wide cohort study of patients aged ≥45 years who had received clarithromycin-based triple therapy for HP infection between 2003 and 2012 in Hong Kong.
Data were retrieved from a public electronic health database. The observation started from receipt of therapy for HP infection to GC diagnosis, death, or the end of the study (December 2015). Exclusion criteria included type 1 DM, GC diagnosed within the 1st year of HP therapy, prior GC or gastrectomy, and retreatment for HP infection. The adjusted hazard ratio (aHR) of GC with type 2 DM was calculated by using a Cox model that adjusted for 20 covariates (age, sex, comorbidities, and medications) through propensity score regression.
- During a median follow-up of 7.1 years (interquartile range 4.8–9.3 years), 153 of 46,460 patients (0.33%) developed GC at a median age of 72.4 years.
- Type 2 DM was associated with an increased risk of GC.
- Stratified analysis showed an increase in risk for cardia cancer only and in those with suboptimal DM control (time-weighted mean HbA1c ≥6.0%.
Based on the findings the authors conclude " Type 2 DM is associated with an increased risk of GC among patients in whom HP was eradicated, in particular, those with gastric cardia cancer and those with suboptimal DM control."
For further reference, click on the link